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www.elsevier.com/locate/jcfLetter to the EditorFig. 1. Determination of the coefficient of correlation (r2) calculated from the
paired comparison of the in vitro antimicrobial susceptibilities of TOBI® versus
BRAMITOB® performed in triplicate in 100 wildtype CF P. aeruginosa isolates.
For ease of visualisation, graph ends at MICb6 μg/ml, but r2 and F-values have
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Sir,
Several guidelines recommend the use of inhaled tobramycin
for the treatment of Pseudomonas aeruginosa lung infections. In
2000, a European consensus statement on antibiotic therapy
against P. aeruginosa advocated the use of appropriate aerosol
administration using colistin or tobramycin throughout the year
[1], whilst in 2005, the Spanish Consensus Group for
Antimicrobial Therapy in the Cystic Fibrosis Patient recom-
mended inhaled tobramycin therapy in several scenarios [2]. In
2007, Flume et al. [3] published the Cystic Fibrosis Pulmonary
Guidelines — Chronic Medications for Maintenance of Lung
Health, which evaluated the evidence for the use of inhaled
tobramycin inmoderate–severe lung disease from several studies,
involving 679 patients in total which concluded that the estimate
of the net benefit was substantial, with the highest level of
evidence. Hence, the use of inhaled tobramycin for the treatment
of P. aeruginosa lung infection in CF is now the standard of care
in many countries.
Two commercial products are currently available for admin-
istration by inhalation, (Tobramycin Inhalation Solution), namely
TOBI® (Novartis AG, Basel, Switzerland), which consists of
tobramycin 300 mg in 5 ml preservative-free saline solution [4],
as well as BRAMITOB® (Chiesi Farmaceuti S.p.A., Parma,
Italy), consisting of tobramycin 300 mg in 4 ml preservative-free
saline [4]. Recently, Chuchalin et al. [4] has compared and
contrasted these two commercially available formulations of
tobramycin, in terms of several parameters including delivery
systems, clinical pharmacokinetics, clinical efficacy and compli-
ance. However, their review did not compare in vitro antimicro-
bial susceptibility of these two agents, nor are there published data
detailing this comparison. Hence, it was the aim of this study to
carry out a direct head-to-head comparison of the antipseudomo-
nal activity of these two agents against the same population of
clinical wildtype P. aeruginosa isolated from adult CF patients.
P. aeruginosa (n=100 isolates) were obtained from 100
adult CF patients attending the Adult Regional CF Centre,
Belfast City Hospital, during the period 1996–2009. Isolates
were selected at random from the CF Microbiology Culture
Archive, housed within the Department of Bacteriology, Belfast
City Hospital. All isolates represented first isolates of P.
aeruginosa in each patient. Following recovery of isolates,1569-1993/$ - see front matter © 2010 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2010.03.005antimicrobial susceptibility testing was performed using the
broth microdilution assay (CLSI M7-A6) (0–64 μg/ml in
doubling dilutions), in accordance with CLSI methodology,
with commercially available preparations of TOBI® and
BRAMITOB®. Each isolate was tested in triplicate against
each formulation of tobramycin with the 100 wildtype P.
aeruginosa CF isolates (600 observations), where the Minimum
Inhibitory Concentration (MIC) value was noted for each
isolate. P. aeruginosa NCTC10662 was used throughout as
control strain and had a MIC value of 0.25 μg/ml for both
agents. Statistical comparison of the paired MIC values
obtained for both agents on the entire collection was performed
using XLFit software (IBDS, Surrey, UK) and the coefficient of
correlation calculated, as shown in Fig. 1. For the 100 wildtype
isolates tested, mean MIC values ranged from 0.125–64 μg/ml
and 0.143–64 μg/ml for TOBI® and BRAMITOB®, respec-
tively. Mean MIC50 and MIC90 values were 0.42 μg/ml and
0.45 μg/ml and 2.00 μg/ml and 2.10 μg/ml, for TOBI® and
BRAMITOB®, respectively. Only 3 isolates (3%) had an MIC
of greater than or equal to 4 μg/ml for both agents (see Fig. 1).
From another study [5], clinical pharmacokinetic studies of both
agents have shown peak sputum concentration of 816±681 μg/
g and 1289±851 μg/g for TOBI and BRAMITOB, respectively,
when used with the Pari TurboBoy/LC Plus and the System 290d by Elsevier B.V. All rights reserved.
238 Letter to the EditorLS nebulizers [5], where the breakpoint was exceeded several
hundred fold by both agents.
To date, no comparative data has been published with regard
to in vitro antimicrobial susceptibility of TOBI versus
BRAMITOB with a similar population of clinical wildtype
CF isolates of P. aeruginosa. This study indicates that there is
no statistical difference (p=0.999) in the in vitro susceptibility
of TOBI and BRAMITOB against CF wildtype P. aeruginosa
and hence both formulations should be considered comparable
with regard to this.
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